To highlight key learning points from the Women's Health Initiative (WHI) studies regarding menopausal hormone therapy (MHT) risks and benefits in postmenopausal women, focusing on specific insights gained over time.
Key Findings:
CEE-MPA and CEE-only therapy significantly reduce fracture risk.
Cardiovascular outcomes are influenced by the timing of MHT initiation, with earlier initiation showing more favorable results.
CEE-MPA therapy increases invasive breast cancer incidence, while estrogen-only therapy shows a nonsignificant reduction.
Both regimens lower colorectal cancer incidence during active treatment.
Early MHT initiation has no effect on cognitive function, while late initiation increases dementia risk.
Interpretation:
WHI findings emphasize the importance of individualized, time-sensitive MHT use, with benefits and risks shaped by formulation, timing, and patient characteristics.
Limitations:
Media coverage emphasized harm, leading to anxiety and premature discontinuation of MHT, which may have skewed public perception.
The studies were limited by selection bias, particularly in the populations studied, and lack of generalizability to broader demographics.
Conclusion:
WHI remains a seminal study that underscores the need for evidence-based, individualized MHT use tailored to age, timing, and baseline risk, with ongoing research necessary to refine clinical guidelines.
